| Name | Title | Contact Details |
|---|
Ecotex Healthcare Laundry services is a Tacoma, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Muhlenberg Regional Medical Center is a Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GEMCare Health Plan is a Bakersfield, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 2001, Regent Surgical Health has led the way in developing and managing successful surgery center partnerships. The ASC model is constantly evolving and Regent positions our facility partners to meet these changing market conditions and succeed. Today, a vast majority of our partnerships are Physician/Hospital Joint Ventures. Our experience has led us to develop proprietary ownership models that give both doctors and hospital administrators what they need to ensure long term clinical and financial success. Our success had earned us a reputation as Joint Venture Specialists. Regent has extensive knowledge of the ASC marketplace. We have found successful financial solutions to increase net revenues rather than using out of network strategies, pioneered new procedures such as spine, cardiology, gastric banding, and knee replacements into the ASC environment, and developed both majority and minority hospital partnerships. At Regent, our track record for successful ASC Turnarounds, De Novos, and Joint Ventures is unmatched.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.